T1	Participants 93 116	neurosurgical patients.
T2	Participants 206 229	neurosurgical patients,
T3	Participants 370 526	Thirty neurosurgical patients were included in a prospective, randomized, double-blinded study comparing esmolol, a short-acting beta-blocker, and a placebo
T4	Participants 1416 1439	neurosurgical patients.
